Finding a cure for the diseases that cause dementia
We believe in the power of research to change the future
Our mission is to bring about the first life-changing dementia treatment by 2025. Our vision is a world where people are free from the fear, harm and heartbreak of dementia.
Diagnosis
Treatments
Causes
Risks
Symptoms
Alzheimer’s Research UK is the UK’s leading dementia research charity, dedicated to causes, diagnosis, prevention, treatment and cure. With your help we are making great progress.
Featured events
Raise money for dementia research and have a great time with one of our events.
Featured news and views
Alzheimer’s Research UK explores impact of isolation in those at risk
Alzheimer’s Research UK has announced funding of new research at the University of Cambridge and Newcastle University exploring the impact of coronavirus-induced social isolation measures on older people at increased risk of COVID-19. Dementia is caused by physical diseases in the brain and recent evidence shows that the condition is linked to a higher risk…
Norwich researcher cycles length of UK in virtual challenge for Alzheimer’s Research UK
Prof Michael Hornberger, from the University of East Anglia, has cycled the 1407km distance between Land’s End and John O’Groats on his indoor bike to raise money for pioneering dementia research. The researcher based at Norwich Medical School, signed up for Alzheimer’s Research UK’s Cycling Down Dementia challenge. Cycling Down Dementia challenges supporters to ride…
Dementia charity spearheads global initiative to use wearables to revolutionise disease detection
The UK’s leading dementia research charity Alzheimer’s Research UK has today (11 February) launched a global initiative to revolutionise the early detection of neurodegenerative diseases like Alzheimer’s. The project will harness and analyse a wealth of digital data to develop signatures of disease – or “fingerprints” – that can be then detected using wearable technologies,…
Halted phase III clinical trial for Alzheimer’s shows renewed promise
Today (Tuesday 22 October) the pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab. Aducanumab is an antibody designed to target amyloid, a protein that builds up in the brains of people with Alzheimer’s at an early stage in the disease process. Biogen originally halted Phase…
-
Untangling frontotemporal dementia
by Fiona Calvert on 29th May 2020
Dementia is thought to affect around 850,000 people in the UK. Most people associate the condition […]
-
You’ll feel tickety-boo with Tikiboo!
by Susie Hewer on 28th May 2020
Have you heard the news about the partnership between Alzheimer’s Research UK and Tikiboo? If […]
-
I’m helping Alzheimer’s Research UK from home, and you can too.
by Jo Spain on 7th May 2020
I’m the events manager at Mattioli Woods and we’ve been supporting Alzheimer’s […]